BridgeBio Pharma (BBIO) EBITDA (2018 - 2026)
BridgeBio Pharma (BBIO) reported EBITDA of -$106.0 million for Q1 2026, down 1.52% on a YoY basis from -$107.6 million in Q1 2025, and up 24.08% sequentially from -$139.6 million in Q4 2025.
BridgeBio Pharma (BBIO) EBITDA (2018 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 9 years of EBITDA data on file, last reported at -$106.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 1.52% year-over-year to -$106.0 million; the trailing twelve-month figure through Mar 2026 stood at -$525.0 million (up 24.75% YoY), and the FY2025 full-year result was -$523.4 million, up 11.73% from the prior year.
- EBITDA improved to -$106.0 million in Q1 2026, from -$139.6 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $343000.0 in Q1 2024 to a low of -$226.0 million in Q4 2024.
- A 5-year average of -$137.8 million and a median of -$139.6 million in 2025 frame the typical range for EBITDA.
- Across the five-year window, EBITDA surged 100.27% in 2024 and slumped 30529.15% in 2025, its largest moves.
- Tracing BBIO's EBITDA over 5 years: stood at -$129.2 million in 2022, then sank by 37.28% to -$177.4 million in 2023, then dropped by 27.4% to -$226.0 million in 2024, then jumped by 38.25% to -$139.6 million in 2025, then increased by 24.08% to -$106.0 million in 2026.
- Business Quant data shows BBIO's EBITDA at -$106.0 million in Q1 2026, -$139.6 million in Q4 2025, and -$145.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn | -105.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -105.96 Mn |
| Dec 31, 2025 | -139.56 Mn |
| Sep 30, 2025 | -145.20 Mn |
| Jun 30, 2025 | -134.28 Mn |
| Mar 31, 2025 | -104.37 Mn |
| Dec 31, 2024 | -226.03 Mn |
| Sep 30, 2024 | -191.75 Mn |
| Jun 30, 2024 | -175.54 Mn |
| Mar 31, 2024 | 343,000.00 |
| Dec 31, 2023 | -177.42 Mn |
| Sep 30, 2023 | -157.69 Mn |
| Jun 30, 2023 | -146.10 Mn |
| Mar 31, 2023 | -126.16 Mn |
| Dec 31, 2022 | -129.23 Mn |
| Sep 30, 2022 | -129.12 Mn |
| Jun 30, 2022 | -80.18 Mn |
| Mar 31, 2022 | -173.68 Mn |
| Dec 31, 2021 | -165.61 Mn |
| Sep 30, 2021 | -149.50 Mn |
| Jun 30, 2021 | -94.02 Mn |